No Data
No Data
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Press Release: Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares SAN FRANCISCO, June 07, 2024 (GLOBE
Structure Therapeutics Is Maintained at Outperform by BMO Capital
Structure Therapeutics Is Maintained at Outperform by BMO Capital
Structure Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/07/2024 79.66% BMO Capital $83 → $100 Maintains Outperform 06/03/2024 16.78% Cantor Fitzgerald $65 → $6
Express News | Structure Therapeutics Inc : BMO Raises Target Price to $100 From $83
Structure Therapeutics Vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?
No Data